Zoetis (ZTS) Income from Non-Controlling Interests (2012 - 2024)
Zoetis (ZTS) reported Income from Non-Controlling Interests of $10.0 million for Q3 2024, up 600.0% quarter-over-quarter from -$2.0 million in Q4 2023.
Zoetis (ZTS) Income from Non-Controlling Interests (2012 - 2024) Analysis & Trends
Zoetis (ZTS) has 12 years of Income from Non-Controlling Interests data on file, last reported at $10.0 million in Q3 2024.
- Income from Non-Controlling Interests for Q3 2024 came in at $10.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $10.0 million (up 600.0% YoY), and the FY2024 annual result was $10.0 million, up 350.0% from the prior year.
- Income from Non-Controlling Interests improved to $10.0 million in Q3 2024 per ZTS's latest filing, from -$2.0 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $10.0 million in Q3 2024 and troughed at -$2.0 million in Q4 2023.
- A 5-year average of -$166666.7 and a median of -$1.0 million in 2020 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2021 and 2023: Income from Non-Controlling Interests changed 0.0% in 2021, then tumbled 100.0% in 2023.
- A 5-year view of Income from Non-Controlling Interests shows it stood at -$1.0 million in 2020, then changed by 0.0% to -$1.0 million in 2021, then changed by 0.0% to -$1.0 million in 2022, then plunged by 100.0% to -$2.0 million in 2023, then jumped by 600.0% to $10.0 million in 2024.
- Business Quant data shows ZTS's Income from Non-Controlling Interests at $10.0 million in Q3 2024, -$2.0 million in Q4 2023, and -$1.0 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 22.56 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | - |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 10.00 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Jun 30, 2023 | -1.00 Mn |
| Mar 31, 2023 | -1.00 Mn |
| Dec 31, 2022 | -1.00 Mn |
| Sep 30, 2022 | -1.00 Mn |
| Mar 31, 2022 | -1.00 Mn |
| Dec 31, 2021 | -1.00 Mn |
| Jun 30, 2021 | -1.00 Mn |
| Mar 31, 2021 | -1.00 Mn |
| Dec 31, 2020 | -1.00 Mn |
| Jun 30, 2020 | -1.00 Mn |
| Jun 30, 2018 | -2.00 Mn |
| Mar 31, 2018 | -2.00 Mn |
| Dec 31, 2017 | -1.00 Mn |
| Oct 1, 2017 | -2.00 Mn |
| Apr 2, 2017 | 1.00 Mn |
| Oct 2, 2016 | -2.00 Mn |
| Dec 31, 2015 | -2.00 Mn |
| Sep 27, 2015 | 1.00 Mn |